DRUGS MADE IN AMERICA ACQ II CORP
DMII
10.19
+0.01
+0.05%
DRUGS MADE IN AMERICA ACQ II CORP
US · DMII
#3572 by market cap
10.19
+0.01
+0.05%
Live - 5344 symbols - heartbeat 316s ago
· 2026-10-07 19:54
After-hours
10.19
0.00%
- Market cap
- 649.10M
- P/E (TTM)i
- 34.90
- P/Bi
- 1.31
- EPSi
- 0.15
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on DMII?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | -- | 488.39K |
| Research & development | -- | -- |
| Operating profit | -- | -1.30M |
| Pretax profit | -- | 4.19M |
| Tax | -- | -- |
| Net profit | -- | 4.19M |
| Basic EPS | -- | 0 |
| Diluted EPS | -- | 0.15 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 59.33K | 38.07K | 155.51K | 235.47K | 132.03K | 112.23K |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -59.33K | -38.07K | -155.51K | -1.05M | -102.03K | -112.23K |
| Pretax profit | -59.33K | -38.07K | -46.16K | 4.33M | 4.34M | 4.40M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -59.33K | -38.07K | -46.16K | 4.33M | 4.34M | 4.40M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.00 | 0.00 | 0.00 | 0.16 | 0.07 | 0.07 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 59.62K | 26.04K |
| Cash & ST investments | 17.04K | 223 |
| Inventory | -- | -- |
| Total assets | 138.06K | 504.96M |
| Total current liabilities | 254.78K | 300.86K |
| Short-term debt | 250.10K | -- |
| Long-term debt | -- | -- |
| Total liabilities | 254,783.00 | 17,800,864.00 |
| Total equity | -116.72K | 487.16M |
| Retained earnings | -151.72K | -17.78M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 11.57K | 11.57K | 896.36K | 26.04K | 351.76K | 217.82K |
| Cash & ST investments | 6.99K | 4.39K | 315.09K | 223 | 347.72K | 174.97K |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 105.10K | 113.40K | 501.01M | 504.96M | 509.73M | 514.10M |
| Total current liabilities | 281.14K | 327.51K | 677.35K | 300.86K | 666.29K | 644.57K |
| Short-term debt | 250.10K | 297.29K | -- | -- | 450.00K | 450.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 281,141.00 | 327,514.00 | 18,177,345.00 | 17,800,864.00 | 18,166,285.00 | 18,144,574.00 |
| Total equity | -176.05K | -214.12K | 482.83M | 487.16M | 491.56M | 495.96M |
| Retained earnings | -211.05K | -249.12K | -17.28M | -17.78M | -17.82M | -17.93M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -- | -1.02M |
| Depreciation & amortization | -- | -- |
| Free cash flow | -- | -1.02M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | 502.00M |
| Ending cash balance | -- | 223 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -10.04K | -2.60K | -690.73K | -314.86K | -102.50K | -172.75K |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -10.04K | -2.60K | -690.73K | -314.86K | -102.50K | -172.75K |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 6.99K | 4.39K | 315.09K | 223 | 347.72K | 174.97K |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | 1.72 |
| ROA %i | -- | 1.66 |
| ROIC %i | -- | 0.12 |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 0.23 | 0.09 |
| Quick ratioi | 0.07 | 0.00 |
| Debt / assetsi | 181.15 | -- |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | 1.72 | 3.49 | 5.25 |
| ROA %i | -- | -- | -- | 1.66 | 3.37 | 5.06 |
| ROIC %i | -- | -- | -- | 0.12 | 1.20 | 1.89 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.04 | 0.04 | 1.32 | 0.09 | 0.53 | 0.34 |
| Quick ratioi | 0.02 | 0.02 | 1.30 | 0.00 | 0.52 | 0.27 |
| Debt / assetsi | 237.98 | 262.17 | -- | -- | 0.09 | 0.09 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.